Select publications

Adjuvant use of aromatase inhibitors

Pharmacokinetics of anastrozole and tamoxifen alone and in combination during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A subprotocol of the "Arimidex® and Tamoxifen Alone or in Combination" (ATAC) trial. Br J Cancer 2001;85(3):317-324. Abstract

Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Breast Cancer Res Treat 2001;69(3):Abstract 8.

Boeddinghaus IM, Dowsett M. Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;79(1-5):85-91. Abstract

Brodie A. Aromatase inhibitors in breast cancer. Trends Endocr Metab 2002;13(2):61-65. Abstract

Buzdar A, Howell A. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001;7:2620-35. Abstract

Buzdar AU. Anastrozole (Arimidex) — an aromatase inhibitor for the adjuvant setting? Br J Cancer 2001;85(2 suppl):6-10. Abstract

Esparza-Guerra L, Buzdar A. Anastrozole 'Arimidex' does not impair adrenal cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer. Proc ASCO 2001;Abstract 1954.

Goss PE. Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res 2001;7(12 suppl):4397s-4401s. Abstract

Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94. Abstract

Hamilton A, Volm M. Nonsteroidal and steroidal aromatase inhibitors in breast cancer. Oncology (Huntingt) 2001;15:965-72; discussion 972, 977-9. Abstract

Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res 2001;7(12 suppl):4402s-4410s. Abstract

Howell A et al. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol 2001;79:227-237. Abstract

Ingle JN. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology (Huntingt) 2001;15:28-34. Abstract

Johnson PE, Buzdar A. Are differences in the available aromatase inhibitors and inactivators significant? Clin Cancer Res 2001;7(12 suppl):4360s-4368s. Abstract

Mamounas EP. Adjuvant exemestane therapy after 5 years of tamoxifen: Rationale for the NSABP B-33 trial. Oncology (Huntingt) 2001;15(5 Suppl 7):35-39. Abstract

Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001;79(1-5):93-102. Abstract

Nicholls H. Aromatase inhibitors continue their ATAC on tamoxifen. Trends Mol Med 2002;8(4):S12-3. Abstract

Pritchard KI. The role of tamoxifen and aromase inhibitors/inactivators in postmenopausal patients. Clin Cancer Res 2001;7(12 suppl):4356s-4359s. Abstract

Ragaz J. Adjuvant trials of aromatase inhibitors: Determining the future landscape of adjuvant endocrine therapy. J Steroid Biochem Mol Biol 2001;79:133-141. Abstract

Toi M et al. Aromatase and aromatase inhibitors. Breast Cancer 2001;8(4):329-332. Abstract

Home · Search